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The simian immunodeﬁciency virus- (SIV-) infected rhesus macaque is the preferred animal model for vaccine development, but
the correlates of protection in this model are not completely understood. In this paper, we document the cytotoxic T lymphocyte
(CTL) response to SIV and its eﬀects on viral evolution in an eﬀort to identify events associated with disease progression regardless
of MHC allele expression. We observed the evolution of epitopes targeted by CTLs in a group of macaques that included long-term
nonprogressing (LTNP), slowly progressing (SP), normally progressing (NP), and rapidly progressing (RP) animals. Collectively,
our data (1) identify novel CTL epitopes from an SP animal that are not restricted by known protective alleles, (2) illustrate that, in
this small study, RP and NP animals accrue more mutations in CTL epitopes than in SP or LTNP macaques, and (3) demonstrate
that the loss of CTL responses to immunodominant epitopes is associated with viral replication increases, which are not controlled
by secondary CTL responses. These ﬁndings provide further evidence for the critical role of the primary cell-mediated immune
responses in the control of retroviral infections.
1.Background
Thereiscompellingevidencethatthevirus-speciﬁccytotoxic
T lymphocyte (CTL) response is an important factor in
the control of human and simian immunodeﬁciency viruses
(HIV and SIV, resp.) in infected individuals. Failures in
antibody-based vaccines emphasize the importance of the
CD8+ T lymphocyte response, but the disappointing results
of the STEP HIV vaccine trial indicates a need for a more
complete understanding of CTL responses in lentiviral infec-
tions [1]. The CTL response is restricted by the repertoire of
major histocompatibility complex (MHC) Class I molecules
that present viral epitopes, and a greater knowledge of these
allele: epitope combinations is vital for identifying antigen-
speciﬁc CTLs and measuring eﬀector functions of antiviral
cellular immunity. In addition, more information is needed
about the selective pressure applied by CTLs to viral epitopes
and how that inﬂuences viral evolution during SIV infection
[2].
The expression of the rhesus macaque major histocom-
patibility complex (MHC) Class I molecule Mamu A∗01
has been determined to be associated with slower disease
progression [3, 4], which is similar to the protective eﬀects of
HLA B∗57 expression in humans [5]. One important tech-
nological development from this research was the creation
of Mamu A∗01 tetramers [6]. Unfortunately, animals with2 Journal of Biomedicine and Biotechnology
Mamu A∗01 are in great demand, and the limited availability
of these animals has slowed research in this area [7]. Other
protective alleles include Mamu B∗17, which was initially
reported as a protective allele that was enriched in long-
term nonprogressor (LTNP) animals [8] ,b u tr e c e n tw o r k
indicates that animals with diﬀerent Mamu B∗17 haplotypes
have divergent disease courses [9]. A third Mamu allele—
B∗08—wasalsoreportedtobeassociatedwithslowerdisease
progression and is enriched in macaque populations that
exhibit LTNP phenotypes [10].
CTL responses during HIV and SIV infection generally
consist of several CTL clones recognizing many diﬀerent
epitopes; the size of those CTL clones can diﬀer substantially
resulting in dominant and subdominant responses [11, 12].
Immunodominance in CTL response is inﬂuenced by several
factors [13], including MHC expression [14], T cell avidity
[15, 16], proteosome processing [17], frequency of na¨ ıve
precursorsspeciﬁcforaviralepitope[18],andviralsequence
variability [19]. It has been shown that in SIV infection
CTL selective pressure is a cause of viral escape mutations
[20–23], and this phenomenon is one, but not the only,
cause of vaccine failure [24, 25]. Escape variants have been
identiﬁed and characterized in Mamu A∗01-[ 26, 27], B∗08-
[23], and B∗17-restricted [25] CTL epitopes, and it has been
shown that these viral escape variants are poorly recognized
by subsequent MHC-matched hosts but can revert to wild
type if CTL selective pressure is removed by transmitting
the mutated viruses to MHC mismatched animals [28–30];
interestingly, SIV can also adapt to the ﬁtness cost of certain
escape mutations by generating compensatory mutations
[29].
This paper presents detailed results from a group of
eight rhesus macaques followed for over 4 years (or until
progressiontodisease)todeterminetheinteractionsbetween
the CTL response and viral evolution in chronic SIV
infection. Our comprehensive analysis of CTL response
monitoring and viral sequencing in animals of varying
disease progression phenotypes enabled us to identify novel
epitopes recognized by antiviral CTL responses. We also
show that, in this study, slow progressors (SPs) and LTNP
animals accrue fewer mutations in CTL epitopes than either
normal or rapid progressor animals (NP and RP, resp.),
and that increased mutations are associated with a lower
CD4+ T cell count. Most importantly, we demonstrate that
a loss of CTL response to immunodominant epitopes can
be associated with disease progression despite the presence
of other subdominant CTL responses. This was observed in
an animal that expressed the protective Mamu A∗01 allele as
well as an animal that expressed no known protective allele.
2.MaterialsandMethods
2.1. Experimental Animals and Tether System. Animal care
and treatment were in accordance with SFBR Institutional
Animal Care and Use Committee (IACUC) approved pro-
tocols. Four Indian origin rhesus macaques (16037, 16040,
16041, and 16044), which had been vaccinated 24 months
prior to this experiment with a Nef -deleted SIVmac239 live
attenuatedvaccine[31],weredeterminedtobevirusnegative
by RT-PCR and virus isolation at the time of challenge. Four
additional Indian-origin, retrovirus-negative na¨ ıve rhesus
macaques (11896, 12416, 12900, and 14757) were used as a
control group. These eight animals were placed on a tether
system during the ﬁrst 4 weeks of infection in order to
demonstrate the usefulness of this technology in the study
of viral immunology during the acute phase of infection.
Details of the placement of the tether system, which allowed
for blood sampling without sedation, are provided elsewhere
[32].
2.2. Viral Challenge and Viral Loads. The animals were
challenged intravenously with 1mL of the pathogenic isolate
SIVmac251 at a dose of 100 TCID50. PBMCs were isolated by
Ficoll-Hypaque separation for use in IFN-γ ELISPOT assays,
CTL functional assays, ﬂow cytometry, and viral isolation.
Lymphocyte phenotyping was performed by multicolor ﬂow
cytometry as described elsewhere [31]. Plasma was utilized
to determine viral loads by (nucleic acid sequence based
analysis) NASBA assay (from Advanced Bioscience Labs,
Inc.) with a lower detection limit of 500 RNA copies per
100μL plasma. NASBA technology was utilized instead of
real-time RT-PCR because all the plasma samples collected
while animals were on tether contained sodium heparin.
For relevant comparison, the chronic viral loads were also
performed with this assay.
2.3. MHC Allele Genotyping. RNA was isolated from
macaque PBMCs with the RNAeasy kit (Qiagen). RNA was
converted to cDNA by ampliﬁcation with reverse transcrip-
tase and random primers. This cDNA was then subjected to
PCRwithaforwardprimercommonforthehumanA,B,and
C alleles and reverse primers speciﬁc for either alleles A or B
[33]. The ampliﬁed fragments were cloned into the pCR2.1
(Invitrogen) plasmid and sequenced. In addition, animals
were screened for Mamu A∗01, A∗02, B∗08,a n dB∗17 by
sequence-speciﬁc PCR as previously described in [34].
2.4. CTL Response Measurement and Epitope Identiﬁcation
by ELISPOT Assay. Peptide-speciﬁc release of IFN-γ from
lymphocytes was measured by ELISPOT in accordance with
the manufacturer’s instructions (U-Cytech, Utrecht, The
Netherlands). SIV-speciﬁc responses were determined with
15-mer overlapping SIV peptides (NIH AIDS Research and
Reference Reagent Program) at a concentration of 2μg/mL.
All conditions were performed in duplicate with a positive
control consisting of cells stimulated with Staphylococcus
enteroto xinAandB(SEA/B),andanegativecontrolofRPMI
containing 0.5% dimethyl sulfoxide (DMSO) (Sigma) alone.
To minimize bias, all plates were counted by one individual
in a blinded fashion.
Responses were normalized for CD8+ T cells determined
by ﬂow cytometry and adjusted for DMSO background per
animal. For those epitopes of known restriction, tetramer
studies were performed to ensure that it was the CD8+ T
lymphocytes that recognized the epitope (data not shown).
For epitopes of unknown restriction, CD107 and CytoxiluxJournal of Biomedicine and Biotechnology 3
(OncoImmunin, Inc.) assays were utilized to determine that
apoptosis of target autologous lymphoblastoid B cells was
peptidespeciﬁc and that the CD8+ T lymphocyte population
was positive for degranulation in a peptide-speciﬁc manner
[32]. Epitopes identiﬁed by IFN-γ ELISPOT are putative
only, because they were determined by single 15-mer pep-
tides or overlapping regions of two or more 15-mer peptides
that contain the 8- to 10-amino acid epitope. To identify
these putative epitopes, PBMCs from each animal were
utilized in ELISPOT assays with peptide pools representing
the full SIVmac239 amino acid sequence. Positive pools
were split into smaller pools, and assays were repeated.
This deconvolution continued until either one single 15-mer
peptide or two overlapping 15-mer peptides were identiﬁed
as peptides that elicited production of IFNγ. No additional
mapping of epitopes was performed in this study.
2.5. Virus Isolation and Epitope Sequencing. PBMCs from
infected animals were cocultured with CEMx174 cells with
orwithoutCD8+lymphocytedepletionwithmagneticbeads
coated with anti-CD8+ antibodies (Dynal). Supernatant
from these cultures was assayed by ELISA for SIV gag
protein p27 [31]. Infected CEMx174 cells from ELISA-
positive samples were collected and DNA extracted with the
PureGeneDNAIsolationKit (GentraSystems)inaccordance
with the manufacturer’s protocols. The DNA was then used
in PCR reactions to amplify fragments of SIV provirus
containing relevant epitopes for Gag, Rev, Vif, Tat, Pol,
and Nef. The primers employed were as follows: GagF,
5 GCCTGGTCAACTCGGTACTC3 ;G a g R,5  GTGGAC-
CTAACTCTATTCCTGTTACAA3 ;V i f F,5  GAAGGGACC-
CGGTGAGCTATTG3 ;V i f R,5  AGGAGGAGGTCCTGG-
TCTCCATC3 ;T a t F,5  GCTGCAGGTTCCCGAGAGCT3 ;
TatR,5  ACAAAACTGGCAATGGTAGCAACACT3 ;P o l F,
5 CAGGTCCCAAAATTCCACTTACCAG3 ,P o l R,5  AAT-
GCCATGAGAAATGCTTCCAATT3 ;N e f F,5  CTCTCT-
GCGACCCTACAGAGG3 ;N e f R,5  GCATTTCGCTCT-
GTATTCAGTC3 . These fragments were then cloned into
pCR2.1 (Invitrogen) and sequenced. A minimum of ﬁve
clones of each gene were sequenced for each time point
for each animal to determine the consensus sequence. Any
diﬀerences in sequence were resolved by repeated cloning
and sequencing. In animals in which virus could not be
isolated by coculture, but viral loads were detected by
NASBA, the viral epitopes were sequenced by utilizing the
viral RNA extracted from plasma for the NASBA assay. In
these samples, a calibrator RNA was added for the NASBA
assay; the calibrator consisted of a mismatched Gag sequence
andthatprecludedourcloningofGagepitopesforthesetime
points.
2.6. Statistical Analysis. All statistical analyses were per-
formed with GraphPad Prism (Windows version 4.03,
GraphPad Software, San Diego, CA). Data was ﬁrst tested
for normality using the Kolmogorov-Smirnov (KS) test,
with the P-value determined by the Dallal and Wilkinson
test. The acute phase data sets of both the vaccinated and
unvaccinated groups failed the normality test (P = .0253
and P<. 0001, resp.). Data were then transformed to log
scaletoaccountforthevariabilityofanimalmodellingandto
improve further statistical analyses by normalizing the data.
Subsequent analyses are detailed in the results and included,
Mann-Whitney comparison of mean responses, as well as
Pearson’s correlation to determine signiﬁcant correlations of
the CTL response over time.
3. Results
3.1. Outcome of SIV Challenge and Expression of Protective
Alleles. Using the tether system to study the acute phase
after viral challenge, we recently demonstrated that all the
macaques inoculated with the live-attenuated SIV vaccine
were protected from pathogenic SIV infection [32]. As Table
1 shows however, while three (16037, 16041, and 16044)
of four animals controlled SIV infection very eﬃciently
and remained SP or LTNP, one vaccinated animal (16040,
Mamu A∗01+) progressed to simian AIDS (SAIDS) at 118
weeks postchallenge. On the other hand, and as expected,
unvaccinated animals became infected with SIV and pro-
gressed to disease at 12 (11896), 16 (12900), and 52 (12416)
weeks postchallenge (WPC); one na¨ ıve animal, however,
spontaneously controlled infection and remained as LTNP
(14757). Three of the four animals that controlled infection
had the protective Mamu A∗01 allele (16037, 16041, and
14757); the na¨ ıve LNTP animal (14757) also had the Mamu
B∗08 allele.
3.2. Epitope Emergence in Slow- and Long- Term Nonpro-
gressors. Table 1 also includes a summary of the epitopes
that were recognized by CTL responses (as measured by
IFN-γ ELISPOT responses) that signiﬁcantly changed over
the course of infection. The epitopes that triggered IFN-γ
ELISPOTresponseswerealsoshowntoinducedegranulation
(surface expression of CD107a) of CD8+ T cells and to
inducekillingofautologouslymphoblastoidBcelllines(data
not shown). The SP/LTNP group included two vaccinated
animals with the Mamu A∗01 allele, 16037 and 16041, and
one naive animal with the Mamu A∗01 and B∗08 alleles,
14757. All animals in the Mamu A∗01 positive subgroup
showed a statistically signiﬁcant positive correlation in the
CTL response to the previously described Mamu A∗01-
restricted immunodominant Gag CTPYDINQM epitope
[35]. None of the viral loads in these animals exceeded
500 RNA genome copies per 100μl of plasma in the 4
years of this study. In addition, unvaccinated animal 14757
had signiﬁcant increases in CTL responses to the recently
reported Mamu B∗08 restricted Nef RRLTARGLL epitope
and to an unreported putative Gag TAPSSGRGGNY epitope
late in infection.
The fourth animal in the SP/LTNP group was the
vaccinated SP animal 16044, who lacked Mamu A∗01,
Mamu B∗08,a n dMamu B∗17 alleles as conﬁrmed by
cloning and sequence-speciﬁc PCR screening, and showed a
signiﬁcantnegativetrendinapreviouslyunreportedputative
Vif epitope YFPCFTAGEVR. The establishment of an early
strong CTL response to the Vif YFPCFTAGEVR epitope,4 Journal of Biomedicine and Biotechnology
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Figure 1: Viral Evolution in an Animal with no Known Protective Mamu Alleles. (a) Comparison of Vif-speciﬁc IFN-γ ELISPOT values
for the vaccinated Mamu-A∗01
−,- B∗08
−,- B∗17
− SP animal 16044 before and after an observed Vif YFPCFTAGEVR to YFPCFAAGEVR
mutation. Statistical analysis was performed using the Mann Whitney test. (b) NASBA viral loads and ELISPOT results for acute (Vif) and
chronic (Gag) epitopes were compared to determine the ability of CTLs targeting either the Gag or Vif epitope to control viral replication.
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Figure 2: Viral Evolution in an Animal with Known Protective Mamu Alleles. (a) Comparison of IFN-γ ELISPOT values for the vaccinated,
Mamu A∗01+ NP animal 16040 before or after the Mamu A∗01-restricted Gag CTPYDINQM to CIPYDINQM, Tat STPESANL to
PTPESANP, and Pol STPPLVRLV to SSPPLVRLV mutations. Statistical analysis was performed using the Mann Whitney test. (b) NASBA
viral loads and IFN-γ ELISPOT results for all three epitopes were plotted to determine the eﬀects of mutations on the control of viral
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Table 1: MHC class I allele and CTL Epitope Summary.
Animal
Number
Vaccination,
Disease
Progression
Mamu alleles CTL Epitope
Signiﬁcant
Trend in CTL
Response
Emergence
of viral
mutants
Restricting
Allele for CTL
Epitope
16037 LAV, LTNP A∗01[1],A
∗02,
A
∗04, Gag CTPYDINQM
∗ Increasing No A
∗01
B
∗07,
B
∗09V
[2] Tat STPESANL Increasing No A
∗01
16041 LAV, LTNP A∗01,A
∗23, B
alleles not Gag CTPYDINQM
∗ Increasing Unknown A
∗01
determined Tat STPESANL Decreasing Unknown A
∗01
14757 None, LTNP A∗01,A
∗04,
A
∗23V, Gag CTPYDINQM
∗ Increasing No A
∗01
B
∗07, B∗08 Nef RRLTARGLL Increasing No B
∗08
Tat STPESANL Increasing Yes A
∗01
Gag TAPSSGRGGNY Increasing No Unknown
16044 LAV, SP A
∗04V, A
∗23,
B
∗3002V, Vif YFPCFTAGEV R
∗P Decreasing Yes Unknown
B
∗09V, B
∗21,
B
∗49 Gag EQIQWMYRQQ
P Decreasing No Unknown
Gag MYNPTNILDVK
P Increasing No Unknown
16040 LAV, NP
(118W)
A∗01,A
∗23V,
B
∗63N Gag CTPYDINQM
∗ Decreasing Yes A
∗01
12416 None, NP
(52W)
A
∗04,
A
∗25N
[3],
B
∗67
Nef RTMSYKLAIDM
P Increasing Yes Unknown
11896 None, RP
(12W) ND ND ND ND ND
12900 None, RP
(16W)
A
∗02, A
∗02V,
A
∗04, B
∗05V,
B
∗07
ND ND ND ND
LAV:live-attenuatedvaccine,LTNP:long-termnonprogressor,SP:slowprog.,NP:normalprog.,RP:rapidprog.,(timeofeuthanasiainweekspost-challenge).
[1]Bolded alleles have been reported as protective.
[2]Variant (less than 5 amino acid changes in α1a n dα2 domains from published sequence of allele listed).
[3]Novel (more than 5 amino acid diﬀerences in α1a n dα2 domains from published sequence of allele listed).
PPutative Epitope, ∗Immunodominant Epitope.
coupled with initial control of SIV replication, implied that
this might be an epitope with protective characteristics. This
epitope is located in a functionally important area of the
Vif protein and is highly conserved across SIV and HIV
strains. The Vif YFPCFTAGEVR epitope showed a threonine
(T) to alanine (A) mutation within the putative epitope
ﬁrst noted at 48 weeks post-challenge with no apparent
increase in viral replication prior to that time. To determine
what eﬀect the CTL response was having in protecting this
animal from progressing to disease, we performed additional
ELISPOT pool studies on fresh and frozen PBMC samples.
As expected, CTL responses to the wild-type peptide were
signiﬁcantly lower at timepoints at which the circulating
virus had mutated (P = .0271, one-tailed Mann Whitney
test, Figure 1(a)), which is consistent with previous studies
on escape mutations and implies that the CTL population
speciﬁc for the wild-type epitope was declining, presumably
because the virus in the animal no longer had the wild-type
epitope. Pool studies on archival PBMC samples identiﬁed
additional epitopes in the Gag protein that were being
targeted by CTLs. The strongest ELISPOT response was seen
with the emergence of the putative Gag MYNPTNILDVK
epitope (<45 WPC versus >45 WPC, P<. 0022, one-
tailed Mann Whitney test) that occurred after 45 weeks
post-challenge, which was concurrent with a signiﬁcant loss
of response to the Vif YFPCFTAGEVR epitope (<45 WPC
versus >45 WPC, P<. 0001, one-tailed Mann Whitney
test). Coincidentally, viral loads steadily increased from this
time point onwards, despite strong CTL responses to Gag
MYNPTNILDVK (Figure 1(b)). Whether the loss of control
over viral replication by CTLs targeting these epitopes was
due to viral escape, an intrinsic deﬁcit of eﬀector functions,
or some other silencing mechanism such as increased PD-1
expression, was not determined.
3.3. Epitope Emergence in Normal and Rapid Progressors. Not
allanimalsharbouringtheprotectiveMamu A∗01allelewere
abletocontrolSIVinfection.Sequencingoftheviralepitopes
in the Mamu A∗01+ 16040 animal that progressed to SAIDS
at 118 weeks post-challenge indicated that a threonine (T)6 Journal of Biomedicine and Biotechnology
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Figure 3:ViralEvolutionandDiseaseProgression.(a)SequencingwasperformedforallrecognizedCTLepitopesintheELISPOTassay(3–5
clones per epitope and 2–3 epitopes per animal) for each animal (6 animals) at all time points that the animal was virus positive (2–5 per
animal) (n = 24–72 clones per analysis). Accumulated mutations were noted and the percent of epitopes that showed mutations (regardless
of the eﬀect of the mutation on CTL responses) were compared between the NP/RP and SP/LTNP groups. (b) CD4 T cell absolute counts
were measured at every time-point in which ELISPOT assays were performed and these counts were compared between animals carrying
virus with wild-type epitopes or mutated epitopes. (c) Comparison of the number of accumulated mutations observed in CTL epitopes in
viral proteins. Statistical analysis was performed using unpaired two-tail t-tests.
to isoleucine (I) mutation was ﬁrst observed in position
2 of the Gag CTPYDINQM epitope at 70WPC. This is a
well characterized escape mutation known to abrogate MHC
binding[26]andwasassociatedwithasigniﬁcantdecreasein
CTL response (Figure 2(a)). Other known escape mutations
were ﬁrst detected at 48 WPC in position 1 and 8 of the
Tat STPESANL epitope (serine to proline, and leucine to
proline) and these have also been reported to abrogate MHC
binding [26]. This is consistent with declining numbers of
CTLs speciﬁc for the wild-type epitope, which would be
expected in animals no longer carrying virus with wild-
type sequence. Interestingly, a threonine (T) to serine (S)
mutation was observed in position 2 of the Mamu A∗01 Pol
STPPLVRLV epitope prior to 48WPC, but was not associated
with a decrease in CTL response (Figure 2(a)). Analysis of
viral loads (Figure 2(b)) illustrated that the Pol STPPLVRLV
epitope was not protective as the viral load increased despite
a CTL response to this epitope.
The unvaccinated normal progressor macaque 12416
(lackingknownprotectivealleles)showedaninitialELISPOT
response to a Gag peptide pool that declined before
individual epitopes could be deconvoluted. This animal
had signiﬁcant ELISPOT response increase over time to a
putative Nef epitope RTMSYKLAIDM. Despite the increased
response to this epitope, the viral load at 54WPC was
420,270RNA genome copies per 100μL of plasma (data not
shown). Neither of the rapid progressors (12900, 11896)
showed any detectable ELISPOT response.
3.4.MutationsinRelationtoDiseaseProgression. We counted
the number of mutations that we identiﬁed for each animal
throughout the course of this study and its relation to disease
progression. We found signiﬁcantly higher percentages of
CTL epitope mutations in the normal or rapid progressing
animals (Figure 3(a)) as compared to SP/LTNP animals.
Animals that carried viruses with wild-type CTL epitopes
maintained signiﬁcantly higher CD4+ T cells counts than
animals with virus that has mutated at CTL epitopes
(Figure 3(b)). To determine patterns in the emergence of
CTL epitope mutations, we also compared the percentage
of mutated CTL epitopes found on each viral protein for all
time points and observed thataccessoryproteins appearedtoJournal of Biomedicine and Biotechnology 7
mutate at a higher frequency than the structural proteins in
this sample (Figure 3(c)).
4. Discussion
Data generated from our studies during the chronic phase of
SIV infection adds to the understanding of viral evolution in
the context of CTL selection by analyzing epitope evolution
over 4 years in slow- and long-term nonprogressors, as well
as normal and rapid progressors. The importance of this
study lies in the observation, albeit in a small group of
animals, that the loss of immunodominant CTL responses
established in acute infection may lead to disease progression
regardless of the expression of known protective class I
MHC alleles. In addition, this increase in viral replication
occurred despite late-emerging CTL responses of similar
magnitude to the one seen for dominant epitopes. Previous
studies using animals with Mamu A∗01 and/or Mamu
A∗02 alleles have demonstrated that the evolution of CTL
responses to subdominant epitopes can arise after loss of
Mamu A∗01 immunodominant responses [36], but a loss of
immunodominant responses is followed by increased viral
replication, even if normal CTL responses to subdominant
epitopes (Pol) are present [20, 37]; our data from the Mamu
A∗01+ animal 16040 (Figure 2) agrees with this observation.
In the same line of evidence, and outside the context of
the Mamu A∗01 allele expression, the loss of the initial
immunodominantVifCTLepitopeinanimal16044,resulted
in increased viral replication and disease progression despite
strongsurgeofsubdominantCTLs(Figure 1).Theseﬁndings
in the SIV system are also in agreement with results from a
case report of a closely studied HIV-infected individual [38]
and a recent study in a large cohort of acutely HIV-infected
individuals that were followed into the chronic phase of
the infection, and that showed that the preservation of the
initial CD8+ T-cell immunodominance patterns from the
acute into the chronic phase of infection was signiﬁcantly
associated with slower CD4+ T-cell decline and subsequent
control of viremia [39]. These results appear to be in conﬂict
with a previous study that found that subdominant CTL
responses may have been associated with in vivo HIV-1
viral control [40]; however, this latter study utilized few
time-points from chronic HIV-infected patients, whereas
the study of Streeck et al. [39], like our study, followed
the CTL evolution of acutely HIV-1-infected subjects that
progressed to chronicity. Similarly to the results of Frahm et
al. [40], Streeck et al. did not ﬁnd an association between
immunodominant CTLs and viral control when samples
from the chronic phase were evaluated; however, like we
report here, the positive correlation was observed when the
immunodominant CTLs that aroused in the acute phase of
infection were still maintained in the chronic phase [39].
Our studies also identiﬁed a novel SIV epitope that
elicited strong CTL responses outside of known protective
class I MHC allele expression. The putative Vif YFPCF-
TAGEVR epitope was the target of a protective CTL response
for a slow progressing animal (16044) that did not express
any known protective allele. This peptide sequence is
highly conserved in various HIV and SIV strains including
SIVsmm, SIVmac, HIV2a, and HIV2b; mutagenesis of the
Vif protein has identiﬁed the same region of the protein as
functionally important, with the mutations in the tyrosine
(Y), phenylalanine (F), or cysteine (C) residues reducing
activity of the protein to 1 to 15% of wild type [41]. This
observation is in agreement with recent studies in HIV-1-
infected individuals that suggest that control of infection
may be associated with acute-phase CD8 responses capable
of selecting for viral escape mutations in highly conserved
regions of the virus [42]. In addition, we demonstrate
that slow- and long-term nonprogressors acquire fewer
mutations in CTL epitopes than normal or rapid progressors
and a higher CD4+ T cell count was associated with CTL
responses to wild-type epitopes (Figure 3). This is similar to
what has been observed for a large cohort of HIV infected
individuals [43] and implies that the protection achieved
with certain alleles can be attributed to a failure of the virus
to accumulate escape mutations.
All these observations combined suggest that natural
containment of AIDS virus replication may be related
to a combination of immunodominance and viral escape
from CD8+ T-cell responses; that is, those individuals who
generate acute dominant CTL that target constrained viral
epitopes may have a better chance to control the infection.
5. Conclusions
This study contributes to the body of knowledge regarding
CTL immune responses in SIV- infected rhesus macaques
and increases our understanding of viral evolution in the
contextofSIVinfection.Althoughthesamplegroupissmall,
our observations are detailed and consistent with previous
reports and contribute to the validation of the SIV/rhesus
macaque model of AIDS. In addition, our identiﬁcation
of novel epitopes provides preliminary data justifying the
continued analysis of CTL populations in these animals
to better understand CTL function. Our data also add to
the understanding of the associations between CTL epitope
mutation and disease progression and CD4+ T cell counts
and imply that accessory proteins accrue mutations more
frequently. Lastly, we show that a loss of immunodominant
immune responses to conserved viral epitopes can lead to
disease progression despite maintained or emerging CTL
responses outside the context of known protective allele
expression, which has implications for the rational selection
of antigens for HIV vaccine design.
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